Drug Trial Radar · NCT07051915
The Holistic Study
Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Sep 15, 2025
Primary completion
Jan 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Ostfold Hospital TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Oslo University Hospital; University Hospital, Akershus; Sykehuset i Vestfold HF; St. Olavs Hospital; Helse Stavanger HF; Sorlandet Hospital HF; University Hospital of North Norway; Haukeland University Hospital; Helse Nord-Trøndelag HF; Helse Fonna; Nordlandssykehuset HF
- First posted
- Jul 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).
Conditions
- Thrombocytopenia Purpura
Interventions
AvatrombopagDrug
Daily tablets
Rituximab (Arm B)Drug
I.V.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of the oral TPO-RA, Avatrombopag, to RituximabTime frame: Assessed at week 28
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.